| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ACR.20393 |
| P953 | full work available online at | http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.20393/fullpdf |
| https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Facr.20393 | ||
| https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.20393 | ||
| P698 | PubMed publication ID | 21452265 |
| P5875 | ResearchGate publication ID | 50937634 |
| P2093 | author name string | Androniki Bili | |
| Sorina Dancea | |||
| H. Lester Kirchner | |||
| Jennifer A. Sartorius | |||
| Mary Chester M. Wasko | |||
| Jana L. Antohe | |||
| Stephanie J. Morris | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis | Q33563669 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis | Q35547305 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Inhibition of hepatic cholesterol biosynthesis by chloroquine | Q41924905 | ||
| Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
| The impact of prevention on reducing the burden of cardiovascular disease | Q43469391 | ||
| A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction | Q43603017 | ||
| Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. | Q44123361 | ||
| Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis | Q44784998 | ||
| Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines | Q46207361 | ||
| Patterns and effectiveness of lipid-lowering therapies in a managed care environment | Q46714754 | ||
| Dyslipoproteinemia in the course of active rheumatoid arthritis | Q67478509 | ||
| Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity | Q69439079 | ||
| Lipid profiles in untreated patients with rheumatoid arthritis | Q78139431 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| hydroxychloroquine | Q421094 | ||
| P304 | page(s) | 530-534 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Arthritis Care and Research | Q15754720 |
| P1476 | title | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | |
| P478 | volume | 63 |
| Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
| Q52567976 | Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis. |
| Q36640598 | Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial |
| Q41921823 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q92464675 | Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment |
| Q38090840 | Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides |
| Q37330468 | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. |
| Q47940789 | Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q37829385 | Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy |
| Q97526732 | Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine |
| Q38115132 | Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q44961170 | Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. |
| Q85042756 | Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy |
| Q43643270 | Disease Factors in Early Rheumatoid Arthritis Are Associated with Differential Risks for Cardiovascular Events and Mortality Depending on Age at Onset: A 10-year Observational Cohort Study |
| Q36573102 | Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q38323310 | Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis |
| Q41863834 | Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats |
| Q38745362 | Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
| Q26748085 | Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist |
| Q87621947 | Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients |
| Q35860938 | Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation |
| Q36877859 | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial |
| Q97646016 | Hydroxychloroquine in Dermatology and Beyond: Recent Update |
| Q39144641 | Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study |
| Q38927961 | Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes |
| Q41914520 | Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q38026796 | Lipid Paradox in Rheumatoid Arthritis: Changes With Rheumatoid Arthritis Therapies |
| Q38554197 | Lipid and Metabolic Changes in Rheumatoid Arthritis. |
| Q92723486 | Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus |
| Q34343906 | Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus |
| Q28070338 | Multimorbidity in rheumatic conditions |
| Q36162860 | Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process |
| Q42342710 | Refractory rheumatoid vasculitis-a therapeutic dilemma |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q38149252 | Rheumatoid arthritis and cardiovascular disease |
| Q36812587 | Rheumatoid arthritis and cardiovascular disease: an update on treatment issues |
| Q87402127 | Rheumatoid arthritis: Rheumatoid vasculitis--down but not out |
| Q50318500 | Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy |
| Q60959818 | Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q37261219 | The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q51104578 | Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients |
Search more.